NEW YORK – S2 Genomics said on Tuesday that Japan's RIKEN Center for Integrated Medical Sciences will evaluate and further develop single-cell sequencing applications on the S2 Genomics' Singulator tissue prep system under and early-access program.
According to Livermore, California-based S2 Genomics, the Singulator platform combines enzymatic and mechanical disruption to produce suspensions of cells or nuclei for downstream single-cell applications.